- “Peptide” names a category, not a treatment: insulin and GLP-1 drugs are peptides, and so are compounds tested in fewer than thirty people.
- BPC-157 has three decades of promising animal work and fewer than thirty human subjects, in uncontrolled pilot studies.
- Before starting, ask which peptide, whether it is approved, where it comes from and who supervises it.
Peptide therapy is offered almost everywhere now, and the word gets used as if it named a treatment. It does not. It names a category — an enormous one.
A peptide is simply a short chain of amino acids, smaller than a protein. That is the whole definition. It says nothing about what the molecule does, whether it is approved, or whether anyone has tested it in people.
Insulin is a peptide. So are the GLP-1 medications used for diabetes and weight loss. Those sit among the most rigorously tested drugs in medicine, with peptide-based therapies now established in diabetes, obesity, oncology and rare disease, and roughly one new peptide drug approved each year (Ji et al., 2024; Xiao et al., 2025).
Other peptides have been given to fewer than thirty people in the history of medicine.
Both are “peptides”. So saying “I am on peptides” carries about as much information as saying “I am on pills”.
Where the evidence is strong, and where it runs out
The peptide most requested in regenerative medicine is BPC-157, a synthetic fifteen-amino-acid chain originally isolated from gastric juice.
Its preclinical record is genuinely impressive. Across three decades of animal studies it has promoted new blood vessel formation through VEGFR2 and nitric oxide signalling, stimulated fibroblast activity, and shown repair effects in tendon and muscle — tissues that heal poorly because they are poorly supplied with blood (McGuire et al., 2025).
Then comes the part that rarely appears in the marketing. In humans, BPC-157 has been examined in three pilot studies totalling fewer than thirty subjects, none of them controlled. No adverse effects were reported, but no rigorous trial has been done (McGuire et al., 2025).
There is also no approved pharmaceutical formulation, no validated dosing regimen, and no completed Phase II trial anywhere (Mateescu et al., 2026). Its measured half-life in plasma is under thirty minutes, while the effects reported in animals last days — a mismatch nobody has yet explained.
The reviewers’ own conclusion is the honest one: BPC-157 should be treated as investigational, and used with caution until proper trials exist. That is not an argument that it does nothing. It is an accurate description of what is and is not known.
What to ask before starting peptides
If you are considering peptide therapy in Medellín, these questions separate a serious center from a storefront.
- Which peptide, by name — and what human evidence exists for that specific one?
- Is it an approved medication, or an investigational compound? Both may be reasonable, but you deserve to know which you are being offered.
- Where does the product come from? Many peptides circulate through non-regulated suppliers, and for several of them no pharmaceutical-grade preparation exists at all.
- Who supervises the treatment, and what will be measured before and after?
Two cautions worth stating plainly. Competitive athletes should verify the status of any peptide with their sporting authority, because non-approved substances are generally prohibited in sport. And anyone with a history of cancer, who is pregnant or breastfeeding, or who is managing a chronic condition needs an individual medical assessment first — peptides act on growth and repair pathways, and that is not neutral in every patient.
Used well, within their evidence, peptides are a legitimate and expanding part of medicine. The problem has never been the molecules. It is the word doing too much work.
- Ask for the peptide by name, and for the human evidence behind that specific one.
- Find out whether you are being offered an approved medication or an investigational compound, and where the product comes from.
- If you compete in sport, have a history of cancer, are pregnant or breastfeeding, or manage a chronic condition, get an individual medical assessment first.
Peptide medicines such as insulin and GLP-1 drugs rest on large human trials. BPC-157, the peptide most requested in regenerative medicine, has three decades of animal studies but fewer than thirty human subjects in uncontrolled pilot studies, no approved formulation and no completed Phase II trial.
- Cyclic peptides for drug development · Angewandte Chemie International Edition, 2024
- Advance in peptide-based drug development: Delivery platforms, therapeutics and vaccines · Signal Transduction and Targeted Therapy, 2025
- Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing · Current Reviews in Musculoskeletal Medicine, 2025
- BPC-157 as an investigational peptide therapeutic: Biopharmaceutical challenges, formulation strategies, and translational development barriers · Pharmaceutics, 2026
Questions
Is “peptide therapy” a single treatment?
No. A peptide is any short chain of amino acids. The category includes insulin and GLP-1 drugs, which rest on large trials, and compounds that have been given to fewer than thirty people.
Is BPC-157 safe?
In humans it has been examined in three uncontrolled pilot studies with fewer than thirty subjects. No adverse effects were reported, but no rigorous trial has been done, so reviewers describe it as investigational and advise caution.
Can athletes use peptides?
Competitive athletes should check the status of any peptide with their sporting authority first, because non-approved substances are generally prohibited in sport.
Do you offer peptide therapy?
They are not one of the core treatments at Stem Cells Colombia; the focus is mesenchymal stem cell therapy from Wharton’s jelly. If you ask for peptides, the doctors review your request and, if it makes sense for you, your coordinator can organize them during your stay in Medellín, with medical oversight.